Ex Vivo Drug Sensitivity Testing and Mutation Profiling

Inclusion Criteria: * Patients aged 21 years or younger at the time of enrollment on this study of any gender, race or ethnicity. * Subjects with suspected or confirmed diagnosis of recurrent or refractory cancer * Subjects who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) * Subjects willing to have a blood draw or buccal swab done for the purposes of genetic testing * Subjects or their parents or legal guardians willing to sign informed consent * Subjects aged 7 to 17 willing to sign assent Exclusion Criteria: * Subjects who do not have malignant tissue available and accessible * The amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling. * Patients with newly diagnosed tumors and tumors that have high (\>90%) cure rate with safe standard therapy.